ERG

West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak

WNVis a positive single-stranded RNA flavivirus of about 11 kb. It primarily infe...

Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology

MILWAUKEE, July 11, 2007 /PRNewswire/ -- A new study suggestsstrong variation in the occurrence of anaphylaxis between thenorthern and southern U.S. Anaphylaxis is a severe allergicreaction that can be fatal without treatment with epinephrine. Thestriking north-south differences in EpiPen prescribing, a marker ofanaphylaxis risk, currently are without explanation. Theinvestigators hypoth...

Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

MALVERN, Pa., June 28, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that Mr. Armando Anido, ChiefExecutive Officer and President, and Mr. Jim Fickenscher, ChiefFinancial Officer, will participate in the 2007 CEUT EmergingGrowth Opportunities Conference to be held July 10 through July 12,2007 at the Mandarin Oriental Hotel in New York City. Mr. Anido issche...

ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 2, 2007 - ViaCell, Inc.(NASDAQ: VIAC) today announced that Marc D. Beer, President andChief Executive Officer of ViaCell, will present an update on itsbusiness activities and product pipeline at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference on Tuesday, July10, 2007 at 3:00 p.m. at the Mandarin Oriental Hotel in New York,NY. A live...

Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference

SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Accelrys, Inc.(NASDAQ:ACCL), the leading provider of scientific businessintelligence software and services, announced today that its CFO,Rick Russo, will present at the C.E. Unterberg, Towbin EmergingGrowth Opportunities Conference in New York on July 11, 2007 at10:30 a.m. ET. The conference will take place at the MandarinOriental Hotel July 10th-12...

Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Metabasis Therapeutics(NASDAQ:MBRX), a biopharmaceutical company focused on thediscovery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases by targeting the liverand liver pathways, announced today that John Beck, senior vicepresident of finance and chief financial officer of Metabasis willpresent at t...

Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

DURHAM, N.C.--(BUSINESS WIRE)--Jul 3, 2007 - InspirePharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L.Shaffer, Ph.D., President and CEO, will present at the C.E.Unterberg, Towbin Emerging Growth Opportunities Conference onWednesday, July 11, 2007 at 11:00 am ET in New York City. The webcast of the presentation will be available on Inspire'sweb site at www.inspirepharm.com...

Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference

SOUTH SAN FRANCISCO, Calif., July 03, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. todayannounced that Eric Bjerkholt, Sunesis' Senior Vice President,Corporate Development and Finance, will present a company update atthe C. E. Unterberg, Towbin Emerging Growth Conference on July 12,2007 at 9:00 a.m. Eastern Time in New York, NY. Interested parties may access the webc...

EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIXPharmaceuticals, Inc. (NASDAQ:EPIX) today announced that Michael G.Kauffman, M.D., Ph.D., chief executive officer of EPIX, isscheduled to present at the C.E. Unterberg, Towbin Emerging GrowthOpportunities Conference on Tuesday, July 10, 2007 at 1:30 p.m.(EDT) at the Mandarin Oriental Hotel in New York, NY. The presentation will be webca...

Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 03, 2007/PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNAcompany, announced today that J. Michael French, Rosetta GenomicsPresident, will present at CE Unterberg, Towbin Emerging GrowthOpportunities Conference on Tuesday, July 10, at 11:00 am EST atthe Mandarin Oriental Hotel in New York. A live audio webcast o...

GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTCBiotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today thatGeoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled topresent on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E.Unterberg, Towbin Emerging Growth Life Opportunities Conference.The conference is being held at the Mandarin Oriental Hotel, NewYork, New York from July...

Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference

BETHESDA, Md., July 05, 2007 /PRNewswire-FirstCall/ -- Micromet,Inc. , a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammatoryand autoimmune diseases, today announced that Dr. Christian Itin,President and Chief Executive Officer of Micromet, Inc., willpresent at the 3rd Annual C.E. Unterberg, Towbin Emerging GrowthConf...

Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference

BOULDER, Colo.--(BUSINESS WIRE)--Jul 5, 2007 - Array BioPharma Inc.(Nasdaq: ARRY) today announced that its Chief Executive Officer,Robert E. Conway, will speak at the C.E Unterbeg, Towbin EmergingGrowth Conference on July 10 in New York City. The public iswelcome to participate in the conference through a webcast on theArray BioPharma website. -0- Event: C.E Unterbeg, Towbin E...

Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- AlfacellCorporation today announced that Lawrence A. Kenyon, executive vicepresident, chief financial officer and corporate secretary, willpresent an overview of the company's product development programsat 8 a.m. EDT on Thursday, July 12, 2007, at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference in New York. The aud...

SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

DUBLIN, Calif., July 06, 2007 /PRNewswire-FirstCall/ --SuperGen, Inc. today announced that Dr. Gregory Berk, Chief MedicalOfficer, will present at the C.E. Unterberg, Towbin Emerging GrowthOpportunities Conference on Thursday, July 12, 2007 at the MandarinOriental Hotel in New York City. SuperGen's presentation at the C.E. Unterberg, Towbin EmergingGrowth Opportunities Conference i...

ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

NEW YORK--(BUSINESS WIRE)--Jul 6, 2007 - ZIOPHARM Oncology, Inc.(NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, ChiefExecutive Officer, will present at the C.E. Unterberg, TowbinEmerging Growth Opportunities Conference on Thursday, July 12, 2007at 2:30 p.m. ET at the Mandarin Oriental Hotel, New York. Dr. Lewiswill provide an overview of the Company and an update on itsclinical deve...

Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference

FORT LEE, N.J.--(BUSINESS WIRE)--Jul 6, 2007 - Neurologix, Inc.(OTCBB:NRGX), a biotechnology company engaged in the development ofinnovative gene therapies for the brain and central nervous system,announced today that the company will present at the Third AnnualC.E. Unterberg Towbin Emerging Growth Conference on Tuesday July10, 2007 at 4:30 pm ET at The Mandarin Oriental Hotel in New York.<...

Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 9, 2007 - Neose Technologies,Inc. (NasdaqGM:NTEC) announced today that it will present at theC.E. Unterberg, Towbin Emerging Growth Opportunities Conferenceheld at the Mandarin Oriental Hotel in New York City from July10-12, 2007. The Company's presentation is scheduled for 2:00 p.m.(EDT) on Tuesday, July 10, 2007. The presentation will be webcastlive and...

Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul 9, 2007 -Icagen, Inc. (NASDAQ: ICGN) today announced that P. Kay Wagoner,Ph.D., Chief Executive Officer, will present at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference in New York City onThursday, July 12th at 2:00 p.m. ET. There will be a live webcast of this presentation from theconference. The webcast will be access...

Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference

RICHMOND, VA., July 9 /CNW/ - Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company focused on the development and approvalof drugs for the treatment of metabolic diseases with unmetmedical needs, today announced that it will present at thisweek's C.E. Unterberg, Towbin (CEUT) Emerging GrowthOpportunities Conference in New York City. The conference, to be held at the Mandarin...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy

ROANOKE, Va.--(BUSINESS WIRE)--Jun 20, 2007 - Researchers from LunaInnovations Incorporated (NASDAQ: LUNA) and Virginia CommonwealthUniversity (VCU) are the first to show that carbon nanospheres,sometimes referred to as "buckyballs," are able to block allergicresponse in human cell culture experiments and mice. These findingsare described in a paper entitled "Fullerene Nanomaterials Inhibit...

Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Hemispherx Biopharma, Inc.(AMEX: HEB), a biopharmaceutical company engaged in the clinicaldevelopment of new drug entities for the treatment of pandemicdisease threats, announced today a new scientific report on theactivity of its experimental therapeutic Ampligen(R) in combinationwith approved anti-influenza agents against highly pathogenic avianinflue...

CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007

Zurich, June 1, 2007-Cytos Biotechnology AG is delighted toinform you about the upcoming scientific presentations of its novelimmunotherapeutic CYT003-QbG10 to treat allergic diseases.Recently, positive clinical results for CYT003-QbG10 were obtainedand will be presented in different sessions at the XXVI Congress ofthe European Academy of Allergology and Clinical Immunology(EAACI), takin...

FDA Announces Audio Broadcasts on Emerging Drug Safety Information

ROCKVILLE, Md., April 20,2007-The U.S. Food and DrugAdministration (FDA) is alerting health care professionals andconsumers to the availability of audio broadcasts that provideemerging drug safety information. The broadcasts, commonly known aspodcasts, can be transmitted to personal computers and personalaudio players. The service is part of the agency's ongoing effort to broadena...

AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage

Clinical Poster Presented at Society for Investigative Dermatology FREEPORT, N.Y., May 16, 2007 /PRNewswire/ -- AGI Dermaticsrecently announced new comparative clinical data that indicatesthat OCTN-1 skin cells have the ability to recognize, transport andutilize L-ergothioneine (EGT) as a protector against oxidativedamage, and importantly, that (EGT) acts as a more powerful andefficient a...

Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy

Cytos Biotechnology reports positive results from placebocontrolled phase IIa study in patients suffering from house dustmite allergy SCHLIEREN (Zurich), Switzerland, May 15, 2007 - Cytos BiotechnologyAG (SWX:CYTN) reported today positive results from a multi-centreand placebo-controlled phase IIa study with different formulationsof CYT003-QbG10, an immunotherapeutic product can...

Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis

DURHAM, N.C.--(BUSINESS WIRE)--May 8, 2007 - InspirePharmaceuticals, Inc. (NASDAQ: ISPH) today announced results of aPhase 2 dose-ranging clinical trial comparing epinastine nasalspray and placebo in patients with seasonal allergic rhinitis. Forthe primary endpoint of improvement in total nasal symptom score,dose-related effects were observed in the trial, with the higherdose (0.1%) achievi...

ANX-201 Drug Combination Demonstrates Synergistic Activity Against Human and Bird Flu Viruses

ADVENTRX Presents Results at International Conference on AntiviralResearch SAN DIEGO, May 03, 2007 /PRNewswire-FirstCall/ -- ADVENTRXPharmaceuticals, Inc. , a biopharmaceutical research anddevelopment company focused on commercializing proprietary productcandidates for the treatment of cancer and infectious diseases,announced today that it presented results demonstrating synergisticactiv...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51

Other Presentations at AACR Highlight Progress in SuperGen'sOncology-Focused Pre-Clinical Pipeline LOS ANGELES, April 19, 2007 /PRNewswire-FirstCall/ -- SuperGenInc. today announced that MP470, its multi-targeted tyrosine kinaseinhibitor, suppresses the Rad51 protein, a critical component ofdouble- stranded DNA repair in cancer cells as part of a series ofpresentations at the 2007 America...

Viventia biotech reports synergystic effect of its Proxinium antibody in combinaton with chemotherapy and radiation

- Results Reported at the American Association for Cancer Research(AACR) Annual Meeting - TORONTO, April 18, 2007 /PRNewswire/ - Viventia Biotech Inc., aprivately held biopharmaceutical company advancing a portfolio ofnovel antibody products focused on cancer, today announced resultsof in vitro cytotoxicity and in vivo pharmacokinetic studiesconducted to evaluate the potential for combini...

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

CALGARY, April 17, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. ("Oncolytics") announces that a poster by Dr. MaureenE. Lane et al. of , New York, entitled "In Vivo Synergy betweenOncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116Xenografts" is scheduled to be presented today at the AmericanAssociation for Cancer Research (AACR) Annual Meeting in LosAngeles, CA. The m...

Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer

PALO ALTO, Calif., April 17, 2007 /PRNewswire-FirstCall/ --Telik, Inc. announced the presentation today of results from aPhase 2 clinical trial of the triplet combination of TELCYTA(R)(canfosfamide HCl, TLK286), carboplatin and paclitaxel in thefirst-line treatment of advanced non-small cell lung cancer. Theresults include highly statistically and clinically significantimprovement in bot...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR

DUBLIN, Calif., April 04, 2007 /PRNewswire-FirstCall/ --SuperGen Inc. announced today that it will have multiplepresentations at the American Association for Cancer ResearchAnnual Meeting on April 14-18 in Los Angeles. These presentationswill focus on data concerning many of SuperGen's current oncologyprograms including its lead tyrosine kinase inhibitor compound,MP470 and its ability to...

Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention

BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - InotekPharmaceuticals Corporation announced today the presentation ofpositive Phase 2 clinical data demonstrating the safety of INO-1001as well as the potential for INO-1001 as a preventative agent forcardiac reperfusion injury. The study was conducted in subjectswith acute ST-elevated myocardial infarction (STEMI) undergoingprimary percutaneo...

MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy

MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC.(NASDAQ: MOGN), a biopharmaceutical company focused in oncology andacute care, today announced that a randomized, double-blind,multi-center, pivotal phase 3 trial of Aquavan(R) (fospropofoldisodium) Injection for sedation of patients undergoingbronchoscopy successfully met its primary endpoint of sedationsuccess as well as all sec...

Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients

SCHLIEREN (Zurich), Switzerland, March 13, 2007 -Cytos Biotechnology AG (SWX:CYTN) reported today positive resultsfrom a phase IIa study with CYT003-QbG10, an immunotherapeuticproduct candidate for the treatment of allergic diseases. The studyincluded 40 patients suffering from mild to moderate allergicrhinitis due to grass pollen allergy (hay fever). The trialinvestigated i...

Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters atthe Annual Meeting of the American Academy of Allergy, Asthma, andImmunology from February 23 - 27, 2007 in San Diego, CA. Theposters discussed findings from a survey of 202 otolaryngologists(ENTs) and allergists in the U.S., U.K., France, and Germany on theburden of chroni...